Medicare-For-Hmmm: A Year Of House Hearings Show Democratic Disunity
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.
You may also be interested in...
It is easy to see why Sen. Bernie Sanders would be the least popular pick for biopharma executives among the contenders in the Presidential race. But for industry lobbyists, it might not be the worst outcome – at least in terms of clarifying positions.
Eric Bastings will lead Division of Neurology I, which is expected to handle Biogen’s Alzheimer’s drug aducanumab and Sarepta’s refiling of golodirsen for DMD next year.
Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.